Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. (2022)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.21203/rs.3.rs-1835695/v1
Publication URI: http://dx.doi.org/10.21203/rs.3.rs-1835695/v1
Type: Preprint